^
Association details:
| Biomarker: | UGP2-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report
Published date:
07/14/2023
Excerpt:
Pathological histology revealed lung adenocarcinoma in the patient. The UGP2-ALK mutation was found by next-generation sequencing. Subsequently, the patient was administered alectinib, and thereafter, the tumor lesion was observed to gradually shrink over the follow-up period. Progression-free survival reached 10 months as of the follow-up date, with no adverse events detected.
DOI:
10.1097/CAD.0000000000001531
